Form D · Pharmaceuticals
CoStim Pharmaceuticals Inc.
Boston, MA · CIK 0001573655
Offering snapshot reported Apr 10, 2013 · SEC filing
- Reported sold
- $10M Offering amount: $22.3M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 29, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 10, 2013 | Initial | $10,005,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-194766
Source: Form D, filed Apr 10, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Luke Evnin | Director |
| Jean Francois Formela | Director |
| Roger Kitterman | Director |
| Robert Millman | Director, Executive |
| Marian Nakada | Director |
| Josh Resnick | Director |
| Kazumi Shiosaki | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
200 Clarendon Street 54 Th Floor
Boston, MA, 02116
Boston, MA, 02116